Cell and Gene Therapy Biomanufacturing CDMO Market Insights and Forecast to 2033

Market Research Report

A quick peek into the report

1.1   Product Definition
1.1.1   Inclusion Criteria for the Report
1.1.2   Exclusion Criteria for the Report
1.2   Market Scope
1.2.1   Scope of the Work
1.2.2   Key Questions Answered in the Report
1.3   Research Methodology
1.3.1   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV: Research Methodology
1.3.2   Data Sources
1.3.2.1   Primary Data Sources
1.3.2.2   Secondary Data Sources
1.3.3   Market Estimation Model
1.3.3.1   Criteria for Company Profiling
1.4   Market Overview
1.4.1   Global Market Scenario
1.4.1.1   Realistic Growth Scenario
1.4.1.2   Optimistic Scenario
1.4.1.2.1   Pessimistic Scenario
1.4.2   Market Footprint and Growth Potential
1.4.3   COVID-19 Impact on Market
1.4.3.1   Impact on Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
1.4.3.1.1   COVID-19 Impact: Current Scenario of the Market
1.4.3.1.2   Pre- and Post-COVID-19 Impact Assessment
1.4.3.1.2.1   Pre-COVID-19 Phase
1.4.3.1.2.2   Post-COVID-19 Phase
1.4.4   Unmet Needs
1.4.4.1   Addressing Unmet Needs in the AAV Manufacturing Process
1.4.4.1.1   Upstream Processing
1.4.4.1.2   Downstream Processing

2.1   Overview
2.2   Regulatory Guidance
2.2.1   Current Good Manufacturing Practice (CGMP) Regulations
2.2.1.1   U.S.
2.2.1.2   Europe
2.3   Quality Aspects of Cell and Gene Therapy by the European Medicines Agency (EMA)
2.3.1   Vector Design
2.3.2   Development Genetics
2.3.3   Drug Substance
2.3.3.1   Manufacture
2.3.3.2   Description of Manufacturing Process and Process Controls
2.3.4   Starting Materials
2.3.5   Characterization
2.3.6   Drug Product
2.3.6.1   Manufacturing of the Drug Product and Process Controls
2.4   U.S. Food and Drug Administration (FDA) Requirements for Viral Vectors
2.4.1   Clinical Safety Evaluations for AAV Vectors

3.1   Overview
3.2   Impact Analysis
3.3   Market Drivers
3.3.1   Rise in Preclinical and Clinical Activities around Viral-Vector-Based Gene Therapies Propelling the Demand for CDMOs in the Market
3.3.2   Increasing Number of Emerging Players in the Cell and Gene Therapy (CGT) Sector Driving the Demand for CDMO Services
3.3.3   High Investment of CDMOs in Advancing Viral-Vector Manufacturing and Research in Gene Therapies
3.4   Market Restraints
3.4.1   Limitations in the Development of Analytical Methods for Large-Scale Adeno-Associated Virus (AAV) Biomanufacturing
3.4.2   High Cost of Viral-Vector Manufacturing Creating a Challenge for Emerging CDMO Players in the Market
3.5   Market Opportunities
3.5.1   Development in the Advancements of AAV Biomanufacturing Facilities by Strategic Collaborations of CDMO Service Provider Companies

4.1   Overview
4.2   Key Strategies and Developments
4.2.1   Synergistic Activities
4.2.2   Product Launches
4.2.3   Acquisitions and Mergers
4.2.4   Product Approvals
4.2.5   Business Expansions, Funding, and Investments
4.3   Market Share Analysis
4.4   Growth-Share Analysis
4.4.1   By Phase of Development
4.5   Supply Chain Analysis
4.5.1   Key Entities in Supply Chain

5.1   Overview
5.2   Clinical Phase I
5.3   Clinical Phase II
5.4   Clinical Phase III
5.5   Commercial Phase

6.1   Overview
6.2   Upstream Processing
6.3   Downstream Processing
6.4   Formulation and Fill and Finish

7.1   Overview
7.2   Oncology
7.3   Ophthalmology
7.4   Infectious Disease
7.5   Metabolic Disorder
7.6   Neurological Disorder
7.7   Other

8.1   Overview
8.2   Adherent Culture
8.3   Suspension Culture

9.1   Overview
9.1.1   North America
9.1.1.1   North America Market Size and Forecast
9.1.1.1.1   North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.1.1.2   North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.1.1.3   North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.1.1.4   North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.1.2   U.S.
9.1.1.2.1   U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.1.2.2   U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.1.2.3   U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.1.2.4   U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.1.3   Canada
9.1.1.3.1   Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.1.3.2   Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.1.3.3   Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.1.3.4   Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.2   Europe
9.1.2.1   Europe Market Size and Forecast
9.1.2.1.1   Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.2.1.2   Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.2.1.3   Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.2.1.4   Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.2.2   U.K.
9.1.2.2.1   U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.2.2.2   U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.2.2.3   U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.2.2.4   U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.2.3   Germany
9.1.2.3.1   Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.2.3.2   Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.2.3.3   Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.2.3.4   Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.2.4   France
9.1.2.4.1   France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.2.4.2   France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.2.4.3   France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.2.4.4   France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.2.5   Italy
9.1.2.5.1   Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.2.5.2   Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.2.5.3   Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.2.5.4   Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.2.6   Spain
9.1.2.6.1   Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.2.6.2   Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.2.6.3   Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.2.6.4   Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.2.7   Rest-of-Europe
9.1.2.7.1   Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.2.7.2   Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.2.7.3   Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.2.7.4   Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.3   Asia-Pacific
9.1.3.1   Asia-Pacific Market Size and Forecast
9.1.3.1.1   Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.3.1.2   Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.3.1.3   Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.3.1.4   Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.3.2   China
9.1.3.2.1   China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.3.2.2   China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.3.2.3   China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.3.2.4   China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.3.3   Japan
9.1.3.3.1   Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.3.3.2   Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.3.3.3   Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.3.3.4   Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.3.4   India
9.1.3.4.1   India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.3.4.2   India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.3.4.3   India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.3.4.4   India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.3.5   Australia
9.1.3.5.1   Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.3.5.2   Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.3.5.3   Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.3.5.4   Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.3.6   South Korea
9.1.3.6.1   South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.3.6.2   South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.3.6.3   South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.3.6.4   South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.3.7   Rest-of-Asia-Pacific
9.1.3.7.1   Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.3.7.2   Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.3.7.3   Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.3.7.4   Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.4   Latin America
9.1.4.1   Latin America Market Size and Forecast
9.1.4.1.1   Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.4.1.2   Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.4.1.3   Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.4.1.4   Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.4.2   Brazil
9.1.4.2.1   Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.4.2.2   Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.4.2.3   Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.4.2.4   Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.4.3   Mexico
9.1.4.3.1   Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.4.3.2   Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.4.3.3   Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.4.3.4   Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.4.4   Rest-of-Latin America
9.1.4.4.1   Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.4.4.2   Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.4.4.3   Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.4.4.4   Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.5   Middle East and Africa
9.1.5.1   Middle East and Africa Market Size and Forecast
9.1.5.1.1   Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.5.1.2   Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.5.1.3   Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.5.1.4   Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.5.2   K.S.A.
9.1.5.2.1   K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.5.2.2   K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.5.2.3   K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.5.2.4   K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.5.3   U.A.E.
9.1.5.3.1   U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.5.3.2   U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.5.3.3   U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.5.3.4   U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.5.4   Israel
9.1.5.4.1   Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.5.4.2   Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.5.4.3   Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.5.4.4   Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.5.5   Türkiye
9.1.5.5.1   Türkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.5.5.2   Türkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.5.5.3   Türkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.5.5.4   Türkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.5.6   South Africa
9.1.5.6.1   South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.5.6.2   South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.5.6.3   South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.5.6.4   South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
9.1.5.7   Rest-of-Middle East and Africa
9.1.5.7.1   Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
9.1.5.7.2   Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
9.1.5.7.3   Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
9.1.5.7.4   Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)

10.1   Overview
10.2   Cell and Gene Therapy Biomanufacturing CDMO – Focused on AAV Ecosystem Active Players
10.3   Company Profiles
10.3.1   AGC Biologics.
10.3.1.1   Company Overview
10.3.1.2   Role of AGC Biologics. in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
10.3.1.3   Key Competitors
10.3.1.4   Financials
10.3.1.5   Corporate Strategies
10.3.1.5.1   Synergistic Activities
10.3.1.5.2   Business Expansions, Funding, and Investments
10.3.1.6   Business Strategies
10.3.1.6.1   Product Launch
10.3.1.7   Analyst Perspective
10.3.2   Charles River Laboratories International, Inc.
10.3.2.1   Company Overview
10.3.2.2   Role of Charles River Laboratories International, Inc. in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
10.3.2.3   Key Competitors
10.3.2.4   Financials
10.3.2.5   Corporate Strategies
10.3.2.5.1   Synergistic Activities
10.3.2.5.2   Business Expansions
10.3.2.6   Business Strategies
10.3.2.6.1   Product Launches
10.3.2.7   Analyst Perspective
10.3.3   Catalent, Inc.
10.3.3.1   Company Overview
10.3.3.2   Role of Catalent, Inc. in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
10.3.3.3   Key Competitors
10.3.3.4   Financials
10.3.3.5   Corporate Strategies
10.3.3.5.1   Synergistic Activities
10.3.3.5.2   Business Expansions
10.3.3.6   Business Strategies
10.3.3.6.1   Product Launches/ Approvals
10.3.3.7   Analyst Perspective
10.3.4   Creative Biogene
10.3.4.1   Company Overview
10.3.4.2   Role of Creative Biogene in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
10.3.4.3   Analyst Perspective
10.3.5   Danaher. (Cytiva)
10.3.5.1   Company Overview
10.3.5.2   Role of Danaher. (Cytiva) in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
10.3.5.3   Key Competitors
10.3.5.4   Financials
10.3.5.5   Key Insights about the Financial Health of the Company
10.3.5.6   Corporate Strategies
10.3.5.6.1   Mergers and Acquisitions
10.3.5.6.2   Synergistic Activities
10.3.5.6.3   Business Expansions
10.3.5.7   Business Strategies
10.3.5.7.1   Product Launches
10.3.5.8   Analyst Perspective
10.3.6   FUJIFILM Diosynth Biotechnologies
10.3.6.1   Company Overview
10.3.6.2   Role of FUJIFILM Diosynth Biotechnologies in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
10.3.6.3   Key Competitors
10.3.6.4   Corporate Strategies
10.3.6.4.1   Synergistic Activities
10.3.6.4.1.1   Business Expansions
10.3.6.5   Analyst Perspective
10.3.7   Genscript Biotech Corporation (GenScript ProBio)
10.3.7.1   Company Overview
10.3.7.2   Role of Genscript Biotech Corporation (GenScript ProBio) in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
10.3.7.3   Key Competitors
10.3.7.4   Financials
10.3.7.5   Key Insights about the Financial Health of the Company
10.3.7.6   Analyst Perspective
10.3.8   Lonza.
10.3.8.1   Company Overview
10.3.8.2   Role of Lonza. in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
10.3.8.3   Key Competitors
10.3.8.4   Financials
10.3.8.5   Business Strategies
10.3.8.5.1   Product Launch
10.3.8.6   Analyst Perspective
10.3.9   Merck KGaA
10.3.9.1   Company Overview
10.3.9.2   Role of Merck KGaA in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
10.3.9.3   Key Competitors
10.3.9.4   Financials
10.3.9.5   Business Strategies
10.3.9.5.1   Product Launch
10.3.9.6   Analyst Perspective
10.3.10   Porton Advanced Solution Ltd.
10.3.10.1   Company Overview
10.3.10.2   Role of Porton Advanced Solution Ltd. in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
10.3.10.3   Key Competitors
10.3.10.4   Corporate Strategies
10.3.10.4.1   Synergistic Activities
10.3.10.5   Analyst Perspective
10.3.11   PackGene Biotech
10.3.11.1   Company Overview
10.3.11.2   Role of PackGene Biotech in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
10.3.11.3   Key Competitors
10.3.11.4   Analyst Perspective
10.3.12   Oxford Biomedica plc
10.3.12.1   Company Overview
10.3.12.2   Role of Oxford Biomedica plc in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
10.3.12.3   Key Competitors
10.3.12.4   Financials
10.3.12.5   Corporate Strategies
10.3.12.5.1   Synergistic Activities
10.3.12.5.2   Business Expansions
10.3.12.6   Analyst Perspective
10.3.13   Thermo Fisher Scientific Inc. (Patheon Pharma Services)
10.3.13.1   Company Overview
10.3.13.2   Role of Thermo Fisher Scientific Inc. (Patheon Pharma Services) in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
10.3.13.3   Key Competitors
10.3.13.4   Financials
10.3.13.5   Key Insights about the Financial Health of the Company
10.3.13.6   Corporate Strategies
10.3.13.6.1   Mergers and Acquisitions
10.3.13.6.2   Business Expansions
10.3.13.7   Business Strategies
10.3.13.7.1   Product Launches
10.3.13.8   Analyst Perspective
10.3.14   WuXi AppTec
10.3.14.1   Company Overview
10.3.14.2   Role of WuXi AppTec in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV
10.3.14.3   Key Competitors
10.3.14.4   Financials
10.3.14.5   Corporate Strategies
10.3.14.5.1   Mergers and Acquisitions
10.3.14.5.2   Synergistic Activities
10.3.14.6   Business Strategies
10.3.14.6.1   Product Launches
10.3.14.7   Analyst Perspective
10.3.15   Emerging Companies
10.3.15.1   Asklepios BioPharmaceutical, Inc. (AskBio)
10.3.15.2   Forge Biologics
10.3.15.3   Takara Bio, Inc.

Table 1:   Key Questions Answered in the Report
Table 2:   Impact Analysis, Market Drivers and Restraints
Table 3:   Pipeline Analysis of Manufactures in AAV-Based Gene Therapy
Table 4:   Investment in Viral-Vector Manufacturing
Table 5:   Limitations Associated with Analytical Method for AAV Quality Control (QC)
Table 6:   Collaboration and Partnerships
Table 7:   North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Impact Analysis
Table 8:   Pipeline AAV-Based Gene Therapies in the U.S.
Table 9:   Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Impact Analysis
Table 10:   Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Impact Analysis
Table 11:   Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Impact Analysis
Table 12:   Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Impact Analysis

Figure 1:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 2:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Impact Analysis
Figure 3:   Key Development Analysis from January 2020 to June 2023
Figure 4:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), % Share, 2022 and 2033
Figure 5:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), % Share, 2022 and 2033
Figure 6:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), % Share, 2022 and 2033
Figure 7:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), % Share, 2022 and 2033
Figure 8:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Region), Market Snapshot
Figure 9:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV Segmentation
Figure 10:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV: Research Methodology
Figure 11:   Primary Research Methodology
Figure 12:   Bottom-Up Approach (Segment-Wise Analysis)
Figure 13:   Top-Down Approach (Segment-Wise Analysis)
Figure 14:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Market Size and Growth Potential (Realistic Scenario), $Million, 2022-2033
Figure 15:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Market Size and Growth Potential (Optimistic Scenario), $Million, 2022-2033
Figure 16:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, Market Size and Growth Potential (Pessimistic Scenario), $Million, 2022-2033
Figure 17:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 18:   Major Impact
Figure 19:   Minor Impact
Figure 20:   Pros and Cons of Upstream Processing
Figure 21:   Pros and Cons of Downstream Processing
Figure 22:   Addressing Substantial Challenges in AAV Manufacturing
Figure 23:   Process of Manufacturing Pharmaceuticals
Figure 24:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV: Market Dynamics
Figure 25:   Clinical Trials in Viral-Vector-Based Gene Therapy from January 2020-May 2023 (by Phase)
Figure 26:   Number of Cell and Gene Therapy Developers (by Region)
Figure 27:   Cost of Goods (CoGs) in Manufacturing Scale
Figure 28:   Cost of Upstream Processing and Downstream Processing in Manufacturing Scales
Figure 29:   Share of Key Developments, January 2020-June 2023
Figure 30:   Number of Product Launches (by Company), January 2020-May 2023
Figure 31:   Market Share Analysis of the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Company), 2022
Figure 32:   Growth-Share Analysis for Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), 2023-2033
Figure 33:   Supply Chain Analysis
Figure 34:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development)
Figure 35:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), % Share, 2022 and 2033
Figure 36:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Clinical Phase I), $Million, 2022-2033
Figure 37:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Clinical Phase II), $Million, 2022-2033
Figure 38:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Clinical Phase III), $Million, 2022-2033
Figure 39:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Commercial Phase), $Million, 2022-2033
Figure 40:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow)
Figure 41:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), % Share, 2022 and 2033
Figure 42:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Upstream Processing), $Million, 2022-2033
Figure 43:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Downstream Processing), $Million, 2022-2033
Figure 44:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Formulation and Fill and Finish), $Million, 2022-2033
Figure 45:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication)
Figure 46:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), % Share, 2022 and 2033
Figure 47:   Some Examples of AAV Vectors Employed in Oncology
Figure 48:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Oncology), $Million, 2022-2033
Figure 49:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Ophthalmology), $Million, 2022-2033
Figure 50:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Infectious Disease), $Million, 2022-2033
Figure 51:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Metabolic Disorder), $Million, 2022-2033
Figure 52:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Neurological Disorder), $Million, 2022-2033
Figure 53:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Other), $Million, 2022-2033
Figure 54:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type)
Figure 55:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), % Share, 2022 and 2033
Figure 56:   Adherent Platform
Figure 57:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Adherent Culture), $Million, 2022-2033
Figure 58:   Suspension Platform
Figure 59:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (Suspension Culture), $Million, 2022-2033
Figure 60:   Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Region)
Figure 61:   North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 62:   North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Country), % Share, 2022 and 2033
Figure 63:   North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 64:   North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 65:   North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 66:   North America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 67:   U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 68:   U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 69:   U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 70:   U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 71:   U.S. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 72:   Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 73:   Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 74:   Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 75:   Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 76:   Canada Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 77:   Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 78:   Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Country), % Share, 2022 and 2033
Figure 79:   Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 80:   Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 81:   Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 82:   Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 83:   U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 84:   U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 85:   U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 86:   U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 87:   U.K. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 88:   Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 89:   Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 90:   Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 91:   Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 92:   Germany Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 93:   France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 94:   France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 95:   France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 96:   France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 97:   France Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 98:   Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 99:   Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 100:   Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 101:   Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 102:   Italy Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 103:   Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 104:   Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 105:   Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 106:   Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 107:   Spain Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 108:   Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 109:   Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 110:   Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 111:   Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 112:   Rest-of-Europe Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 113:   Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 114:   Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Country), % Share, 2022 and 2033
Figure 115:   Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 116:   Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 117:   Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 118:   Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 119:   China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 120:   China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 121:   China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 122:   China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 123:   China Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 124:   Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 125:   Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 126:   Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 127:   Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 128:   Japan Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 129:   India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 130:   India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 131:   India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 132:   India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 133:   India Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 134:   Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 135:   Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 136:   Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 137:   Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 138:   Australia Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 139:   South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 140:   South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 141:   South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 142:   South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 143:   South Korea Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 144:   Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 145:   Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 146:   Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 147:   Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 148:   Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 149:   Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 150:   Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Country), % Share, 2022 and 2033
Figure 151:   Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 152:   Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 153:   Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 154:   Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 155:   Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 156:   Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 157:   Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 158:   Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 159:   Brazil Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 160:   Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 161:   Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 162:   Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 163:   Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 164:   Mexico Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 165:   Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 166:   Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 167:   Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 168:   Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 169:   Rest-of-Latin America Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 170:   Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 171:   Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Country), % Share, 2022 and 2033
Figure 172:   Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 173:   Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 174:   Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 175:   Middle East and Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 176:   K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 177:   K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 178:   K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 179:   K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 180:   K.S.A. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 181:   U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 182:   U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 183:   U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 184:   U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 185:   U.A.E. Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 186:   Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 187:   Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 188:   Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 189:   Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 190:   Israel Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 191:   Türkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 192:   Türkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 193:   Türkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 194:   Türkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 195:   Türkiye Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 196:   South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 197:   South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 198:   South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 199:   South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 200:   South Africa Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 201:   Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV, $Million, 2022-2033
Figure 202:   Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), $Million, 2022-2033
Figure 203:   Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Workflow), $Million, 2022-2033
Figure 204:   Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Indication), $Million, 2022-2033
Figure 205:   Rest-of-MEA Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Culture Type), $Million, 2022-2033
Figure 206:   Total Number of Companies Profiled
Figure 207:   AGC Biologics.: Service Portfolio
Figure 208:   AGC Biologics.: Overall Financials, $Million, 2020-2022
Figure 209:   AGC Biologics.: Revenue (by Segment), $Million, 2020-2022
Figure 210:   Charles River Laboratories International, Inc.: Service Portfolio
Figure 211:   Charles River Laboratories International, Inc.: Overall Financials, $Million, 2020-2022
Figure 212:   Charles River Laboratories International, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 213:   Charles River Laboratories International, Inc.: Revenue (by Region), $Million, 2020-2022
Figure 214:   Catalent, Inc.: Service Portfolio
Figure 215:   Catalent, Inc.: Overall Financials, $Million, 2020-2022
Figure 216:   Catalent, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 217:   Catalent, Inc.: Revenue (by Region), $Million, 2020-2022
Figure 218:   Creative Biogene: Service Portfolio
Figure 219:   Danaher. (Cytiva): Service Portfolio
Figure 220:   Danaher. (Cytiva): Overall Financials, $Million, 2020-2022
Figure 221:   Danaher. (Cytiva): Revenue (by Segment), $Million, 2020-2022
Figure 222:   Danaher. (Cytiva): Revenue (by Region), $Million, 2020-2022
Figure 223:   Danaher. (Cytiva): R&D Expenditure, $Million, 2020-2022
Figure 224:   FUJIFILM Diosynth Biotechnologies: Service Portfolio
Figure 225:   Genscript Biotech Corporation (GenScript ProBio): Service Portfolio
Figure 226:   Genscript Biotech Corporation (GenScript ProBio): Overall Financials, $Million, 2020-2022
Figure 227:   Genscript Biotech Corporation (GenScript ProBio): Revenue (by Segment), $Million, 2020-2022
Figure 228:   Genscript Biotech Corporation (GenScript ProBio): Revenue (by Region), $Million, 2020-2022
Figure 229:   Genscript Biotech Corporation (GenScript ProBio): R&D Expenditure, $Million, 2020-2022
Figure 230:   Lonza.: Service Portfolio
Figure 231:   Lonza.: Overall Financials, $Million, 2020-2022
Figure 232:   Lonza.: Revenue (by Segment), $Million, 2021 and 2022
Figure 233:   Merck KGaA: Service Portfolio
Figure 234:   Merck KGaA: Overall Financials, $Million, 2020-2022
Figure 235:   Merck KGaA: Revenue (by Segment), $Million, 2020-2022
Figure 236:   Merck KGaA: Revenue (by Region), $Million, 2020-2022
Figure 237:   Porton Advanced Solution Ltd.: Service Portfolio
Figure 238:   PackGene Biotech: Service Portfolio
Figure 239:   Oxford Biomedica plc: Service Portfolio
Figure 240:   Oxford Biomedica plc: Overall Financials, $Million, 2020-2022
Figure 241:   Oxford Biomedica plc: Revenue (by Segment), $Million, 2020-2022
Figure 242:   Oxford Biomedica plc: Revenue (by Region), $Million, 2020-2022
Figure 243:   Thermo Fisher Scientific Inc. (Patheon Pharma Services): Service Portfolio
Figure 244:   Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022
Figure 245:   Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 246:   Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2020-2022
Figure 247:   Thermo Fisher Scientific Inc.: R&D Expenditure, 2020-2022
Figure 248:   WuXi AppTec: Service Portfolio
Figure 249:   WuXi AppTec: Overall Financials, $Million, 2020-2022
Figure 250:   WuXi AppTec: Revenue (by Segment), $Million, 2021 and 2022

Cell and Gene Therapy Biomanufacturing CDMO Market Report Coverage

Key Market Players and Competition Synopsis

The global market for cell and gene therapy biomanufacturing CDMO market- focused on AAV is experiencing substantial growth in coming years. The AAV-based gene therapies have shown significant potential in treating various diseases, leading to a high demand for CDMOs specialized in manufacturing these therapies. Collaborations between therapy developers and CDMOs are expected to accelerate the availability of these groundbreaking treatments, ultimately transforming patient care and revolutionizing treatment of genetic disorders and other serious conditions. As the market evolves, CDMOs must continue to invest in cutting-edge technologies, quality systems, and regulatory compliance to meet the increasing demand for AAV-based cell and gene therapies. The high demand for the therapies is driving the growth of cell and gene therapy CDMO biomanufacturers- focused on AAV and creating ample opportunities for them to expand in various geographies and strengthen their market presence.

Key Companies Profiled:

•   AGC Biologics.
•   Charles River Laboratories International, Inc.
•   Catalent, Inc.
•   Creative Biogene
•   Danaher. (Cytiva)
•   FUJIFILM Diosynth Biotechnologies
•   Genscript Biotech Corporation (GenScript ProBio)
•   Lonza.
•   Merck KGaA
•   Porton Advanced Solution Ltd.
•   PackGene Biotech
•   Oxford Biomedica plc
•   Thermo Fisher Scientific Inc. (Patheon Pharma Services)
•   WuXi AppTec

How can this report add value to an organization?

Workflow/Innovation Strategy: The cell and gene therapy biomanufacturing CDMO market- focused on AAV (by clinical phases) comprises clinical phase I, clinical phase II, clinical phase III, and commercial phase. Moreover, the study provides the reader with a detailed understanding of the different stages involved in workflow for manufacturing of AAV-based therapies such as upstream processing, downstream processing, and formulation fill & finish.

Growth/Marketing Strategy: Emphasize the CDMO's specialization in AAV-based biomanufacturing for cell and gene therapies. The strategic collaborations with therapy developers, academic institutions, and research organizations to be involved in the early stages of gene therapy development. These partnerships can facilitate long-term relationships and secure a pipeline of projects. In addition, Maintain rigorous quality control standards and ensure compliance with global regulatory requirements.

Competitive Strategy: Key players in the global cell and gene therapy biomanufacturing CDMO market - focused on AAV have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the global cell and gene therapy biomanufacturing CDMO market - focused on AAV has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Cell and Gene Therapy Biomanufacturing CDMO Industry and Technology Overview

The global cell and gene therapy biomanufacturing CDMO market - focused on AAV was valued at $231.3 million in 2022 and is anticipated to reach $2,566.6 million by 2033, witnessing a CAGR of 24.61% during the forecast period 2023-2033. The growth in the global cell and gene therapy biomanufacturing CDMO market- focused on AAV is expected to be driven by the rise in clinical activities around viral-vector based gene therapies and high investments of CDMOs in advancing viral-vector manufacturing and research in gene therapies.

Market Lifecycle Stage

The global cell and gene therapy biomanufacturing CDMO market- focused on AAV is currently in a progressing phase. AAV-based gene therapies have gained significant attention and research interest, leading to a higher demand for CDMOs in this market. This increased interest is mainly driven by the potential of AAV-based therapies to treat various genetic disorders and diseases.

Furthermore, partnerships and collaborations between therapy developers and CDMOs play a crucial role in accelerating the availability of cutting-edge AAV-based therapies. By working together, cell and gene therapy developers can focus on their research and clinical activities while outsourcing the manufacturing aspects to CDMOs. This approach enables faster production and time-to-market for these innovative therapies. Additionally, substantial investments in research and development have further fueled advancements in this area, encouraging the exploration of new therapeutic possibilities.

Despite the positive outlook, the global cell and gene therapy biomanufacturing CDMO market- focused on AAV also faces some challenges. One significant challenge is ensuring scalability and maintaining strict quality control standards. As the demand for AAV-based therapies increases, CDMOs need to adapt their manufacturing processes to handle larger production volumes without compromising product quality.

Moreover, the market is becoming more competitive as more CDMOs enter the space to meet the growing demand. This intensified competition could lead to price pressures and potential reductions in profit margins, which may impact the business viability of CDMOs.

Furthermore, the market offers substantial opportunities for all involved parties. Collaborations between CDMOs and therapy developers can drive advancements in AAV biomanufacturing facilities, leading to more efficient and cost-effective production processes. These advancements can further contribute to the overall growth of the market.

Impact

The impact on the global cell and gene therapy biomanufacturing CDMO market- focused on AAV, would be influenced by several factors such as the growing attention and research activities surrounding AAV-based gene therapies would lead to a surge in demand for CDMOs with expertise in AAV biomanufacturing. This increased demand would create more business opportunities for existing CDMOs and attract new players to enter the market. Moreover, the collaborations between therapy developers and CDMOs would foster faster commercialization of AAV-based therapies. This would not only benefit therapy developers by accelerating their time-to-market but also boost the growth of CDMOs, as they establish themselves as reliable partners in the industry. This increasing number of CDMOs entering the market to cater to the rising demand might intensify competition. This could potentially lead to price pressures, as CDMOs may compete to offer competitive rates to secure contracts with therapy developers.

In addition, advancements in AAV biomanufacturing technology could lead to more efficient and cost-effective production processes. CDMOs that adopt these technological innovations would have a competitive advantage, attracting more clients and expanding their market share. However, ensuring scalability in AAV biomanufacturing would be a significant challenge for CDMOs. The ability to handle larger production volumes while maintaining high-quality standards is crucial to meeting the growing demand. CDMOs that can overcome these challenges effectively would be in a better position to thrive in the market.

Impact of COVID-19

The COVID-19 pandemic has had both major and minor impacts on the cell and gene therapy biomanufacturing CDMO market with a focus on AAV.

The following figure depicts the major impact on cell and gene therapy biomanufacturing CDMO market.

Figure: Major Impact

Source:- Qiu T. et al, 2021, “The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects”, NCBI, and BIS Research Analysis

Operational disruptions caused by lockdowns, restrictions, and supply chain challenges led to delays in manufacturing processes and project timelines. Moreover, clinical trials involving AAV-based therapies also faced disruptions due to enrollment challenges, site closures, and regulatory hurdles, affecting CDMOs involved in providing services in these trials. The pandemic has highlighted the importance of adaptability and resilience in the biomanufacturing sector and as the situation stabilizes, the industry is expected to recover and continue driving advancements in AAV-based therapies.

The following figure demonstrate the minor impact of COVID-19 on the market.

Figure: Minor Impact

Source:- Qiu T. et al, 2021, “The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects”, NCBI, and BIS Research Analysis

The uncertain economic environment resulted in cautious funding and investment decisions, impacting the availability of financial resources for CDMOs, and potentially slowing down their expansion plans and technological advancements. In addition, regulatory processes experienced delays and changes as regulatory agencies, including the FDA, redirected resources to address pandemic-related concerns. This could have affected the approval timelines for AAV-based therapies and the manufacturing activities associated with them.

Market Segmentation:

Segmentation 1: by Phase of Development
•   Clinical Phases I
•   Clinical Phases II
•   Clinical Phases III
•   Commercial Phase

Figure: Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV (by Phase of Development), % Share, 2022 and 2033

Source: BIS Research Analysis

Commercial Phases to Continue its Dominance in the Phase of Development Segment

Based on phase of development, the commercial phase segment dominated the global cell and gene therapy biomanufacturing CDMO market- focused on AAV in FY2022. As more AAV-based therapies continue to advance through clinical phases and gain approval, the commercial phase segment is likely to remain a key driver of growth in the CDMO market.

Segmentation 2: by Workflow
•   Upstream Processing
•   Downstream Processing
•   Formulation, Fill & Finish

Downstream Processing to Continue its Dominance in the Workflow Segment

Based on workflow, the downstream processing segment dominated the global cell and gene therapy biomanufacturing CDMO market- focused on AAV in FY2022. The downstream processing segment encompasses the steps involved after the initial cell culture and vector production, where the focus is on purification, filtration, and isolation of the therapeutic AAV vectors.

Segmentation 3: by Indication
•   Oncology
•   Ophthalmology
•   Infectious Diseases
•   Metabolic Disorder
•   Neurological Disorder
•   Other

Oncology to Continue its Dominance in the Indication Segment

Based on indication, the oncology segment dominated the global cell and gene therapy biomanufacturing CDMO market- focused on AAV in FY2022. The dominance of the oncology segment can be attributed to several factors. Cancer continues to be a significant global health challenge, with a high incidence rate in various regions. The prevalence of cancer and the unmet medical need for effective treatments drove increased research and development in oncology-focused cell and gene therapies

Segmentation 4: by Culture Type
• Adherent Culture
• Suspension Culture

Adherent Culture to Continue its Dominance in the Culture Type Segment

Based on culture type, the adherent culture segment segment dominated the global cell and gene therapy biomanufacturing CDMO market- focused on AAV in FY2022. Adherent cell cultures often yield higher cell densities and higher productivity compared to other culture types. This increased productivity is crucial for generating sufficient quantities of AAV vectors needed for commercial production.

Segmentation 5: by Region
•   North America
•   Europe
•   Asia-Pacific
•   Latin America
•   Middle East and Africa

North America cell and gene therapy biomanufacturing CDMO market- focused on AAV is expected to have a market share value of 40.92% in 2022 and is currently the leading contributor to the market. However, the Asia-Pacific region, constituting several emerging economies, is expected to register the highest CAGR of 26.66% during the forecast period, 2023-2033.

Recent Developments in the Global Cell and Gene Therapy Biomanufacturing CDMO Market- Focused on AAV

•   In March 2023, Remedium Bio and Biovian Oy collaborated agreement to work together on the development of Remedium's innovative disease modifying AAV gene therapy for Osteoarthritis. This agreement aims to advance the research and production of groundbreaking therapy, potentially offering new treatment options for patients with Osteoarthritis.
•   In March 2023, Porton Advanced Solutions Ltd. collaborated with DanausGT Biotechnology Co., Ltd. to expedite gene and cell therapy pipelines and develop innovative therapeutics. Porton Advanced, an end-to-end gene and cell therapy service provider, offered comprehensive solutions to DanausGT, including plasmids, viruses, and cell therapy products. The collaboration combined Porton Advanced's expertise with DanausGT's proprietary CRISPR/AAV technology, accelerating the development of cutting-edge Cell and Gene Therapy (CGT) therapeutics.
•   In May 2023, Life Biosciences collaborated with Forge Biologics to advance the development of gene therapies for aging-related diseases. Forge Biologics provided AAV process development, toxicology, cGMP manufacturing, and analytical services using their proprietary platform processes. The collaboration aimed to accelerate the production and delivery of innovative gene therapies for these diseases.
•   In May 2023, AGC Biologics introduced its BravoAAV viral vector platforms, which provided rapid, efficient, and consistent clinical and commercial GMP production and release. These platforms capitalized on AGC Biologics' extensive experience in Adeno-Associated Viral vector (AAV) development, manufacturing, and analytical expertise accumulated over three decades.
•   In March 2023, Charles River Laboratories Inc., launched a Helper Plasmid to streamline the manufacturing process of AAV vectors. This development aimed to enhance efficiency and simplify the production of AAV vectors, a crucial component in gene therapy manufacturing.

Demand – Drivers, Restraints and Opportunities

Market Demand Drivers:

•   Rise in Preclinical and Clinical Activities around Viral-Vector Based Gene Therapies Propel the Demand for CDMOs in the Market
•   Increasing Number of Emerging Players in the Cell and Gene Therapy (CGT) Sector Upsurge the Demand for CDMOs Services
•   High Investment of CDMOs in Advancing Viral-vector Manufacturing and Research in Gene Therapies

Market Restraints:

• Limitations in Development of Analytical Methods for Large-scale Adeno-associated virus (AAV) Biomanufacturing
• High Cost of Viral-vector Manufacturing Creates a Challenge for Emerging CDMOs player in the Market

Market Opportunities:

• Development in the Advancements of AAV Biomanufacturing Facilities by Strategic Collaborations of CDMO Services

Analyst View

According to Akash Mhaskar, Principal Analyst, BIS Research, “The global cell and gene therapy biomanufacturing CDMO market- focused on AAV is in progressing phase and it is expected to rapidly increase in the forecast period. The market is fueled by the rising demand for AAV-based gene therapies for the treatment of various genetic disorders and diseases. These therapies hold great promise in addressing unmet medical needs, driving research, development, and manufacturing efforts. In addition, here have been substantial investments in research and development to advance AAV-based gene therapies. Increased funding and collaborations have accelerated the development of cutting-edge therapies, contributing to the market's growth."

Cell and Gene Therapy Biomanufacturing CDMO Market - Focused on AAV - A Global and Regional Analysis

Focus on Phase of Development, Workflow, Indication, Culture Type, and Region - Analysis and Forecast, 2023-2033

Get Free Sample

Schedule a Call

Some Faq's

Frequently Asked Questions

The cell and gene therapy biomanufacturing CDMO market, focused on AAV, refers to the specific segment within the broader contract development and manufacturing organization (CDMO) industry that specializes in providing manufacturing services for cell and gene therapies, with a particular focus on AAV-based therapies. The CDMOs operating in this market play a vital role in helping therapy developers advance their AAV-based gene therapies from early research stages through preclinical and clinical trials to eventual commercialization. They provide the necessary infrastructure, manufacturing capabilities, and regulatory expertise to ensure the efficient and compliant production of AAV vectors at scale.

There was a growing demand for AAV-based gene therapies across various therapeutic areas, driving the need for CDMOs with specialized AAV biomanufacturing capabilities. CDMOs were increasingly forming strategic partnerships and collaborations with therapy developers and academic institutions to facilitate the development and commercialization of AAV-based therapies. Automation and process optimization were becoming more CDMOs were expanding their geographic presence to serve a broader client base and tap into emerging markets for AAV-based gene therapies.prevalent in AAV biomanufacturing, enhancing productivity and reducing manufacturing timelines.These are only a few illustrations of the major developments in the industry for cell and gene therapy manufacturing. Emerging innovations and technologies are anticipated to emerge as the area develops further, helping to influence the industry's future.

The global cell and gene therapy biomanufacturing CDMO market- focused on AAV is currently witnessing several developments, primarily aimed toward bringing new products and services. Major manufacturers of AAV-based cell and gene therapies, along with the service providers, are actively undertaking significant business strategies to translate success in research and development into the commercial clinical setting. Companies such as Merck KGaA, Lonza., Thermo Fisher Scientific Inc., and WuXi AppTec. have majorly adopted partnerships, collaborations, and joint venture strategies.

For a new company looking to enter the global market for cell and gene therapy biomanufacturing CDMO, focused on AAV, the company should pay attention to several important aspects. Firstly, they should invest in advanced manufacturing facilities that comply with quality standards to ensure reliable and efficient production. Being able to handle different production scales will attract a diverse range of clients. Quick turnaround times and providing technical support are crucial in this time-sensitive industry. Understanding and navigating regulatory requirements is essential for gaining approval for gene therapies. Staying up-to-date with the latest research and innovations will keep the company at the forefront of the field.

•   The vast segmentation of the report such as clinical phases, workflow and indication, among others
•   Market value and forecast of all the segments at regional and country level.
•   Supply chain analysis of cell and gene therapy biomanufacturing CDMOs market- focused on AAV
•   Competitive Benchmarking of key players for each of the key players of cell and gene therapy biomanufacturing CDMOs
•   Growth share analysis for key segments
•   Global market scenarios and unmet needs
•   The report also comprises key regulations, competitive landscape, key drivers and restraints, and company profiles with a detailed analysis of the strategies undertaken by the major company

•   Companies that provide CDMO services for AAV-based cell and gene therapy biomanufacturing
•   Any new entrant that wants to know where the opportunities lie in the cell and gene therapy biomanufacturing
•   Any cell and gene therapy developers who wants to expand their portfolio with the help of CDMOs services

Nucleic Acid Therapeutics CDMO Market - A Global and Regional Analysis: Focus on Chemical Synthesis

The global nucleic acid therapeutics CDMO market was valued at $3.88 billion in 2022 and is...

View Report

Published Year: 2023

Cell and Gene Therapy Biomanufacturing Market - A Global and Regional Analysis: Focus on Product Typ

The global cell and gene therapy biomanufacturing market was valued at $12.31 billion in 2022...

View Report

A quick peek into the report

Table of Contents

Cell and Gene Therapy Biomanufacturing CDMO Market Report Coverage

How can this report add value to an organization?

Cell and Gene Therapy Biomanufacturing CDMO Industry and Technology Overview

$5500

Cell and Gene Therapy Biomanufacturing CDMO Market - Focused on AAV - A Global and Regional Analysis

Frequently Asked Questions

You may also like

Nucleic Acid Therapeutics CDMO Market - A Global and Regional Analysis: Focus on Chemical Synthesis

Cell and Gene Therapy Biomanufacturing Market - A Global and Regional Analysis: Focus on Product Typ

Cell and Gene Therapy Biomanufacturing CDMO Market - Focused on AAV - A Global and Regional Analysis

A quick peek into the report

Table of Contents

1 Markets

2 Industry Analysis

3 Market Dynamics

4 Competitive Landscape

5 By Phase of Development

6 By Workflow

7 By Indication

8 By Culture Type

9 By Region

10 Company Profiles

List of Tables

List of Figures

Cell and Gene Therapy Biomanufacturing CDMO Market Report Coverage

How can this report add value to an organization?

Cell and Gene Therapy Biomanufacturing CDMO Industry and Technology Overview

$5500

Cell and Gene Therapy Biomanufacturing CDMO Market - Focused on AAV - A Global and Regional Analysis

Frequently Asked Questions

Q: What is cell and gene therapy biomanufacturing CDMO market- focused on AAV?

Q: What are the key trends in the cell and gene therapy biomanufacturing CDMO market- focused on AAV?

Q: What kinds of new strategies are being adopted by the existing market players to strengthen their market positions in the industry?

Q: For a new company looking to enter the global cell and gene therapy biomanufacturing CDMO market- focused on AAV, which areas could it focus on to stay ahead of the competition?

Q: What is the USP of this report?

Q: Who should buy this report?

You may also like

Nucleic Acid Therapeutics CDMO Market - A Global and Regional Analysis: Focus on Chemical Synthesis

Cell and Gene Therapy Biomanufacturing Market - A Global and Regional Analysis: Focus on Product Typ